An intravenous formulation of suramin (PAX-101, PaxMedica) reduced several core symptoms of autism spectrum disorder (ASD) in a phase 2 study, according to the company, which released topline results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results